Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells

The anti-CD20 monoclonal antibody, rituximab, provides a significant therapeutic benefit for patients with B-cell disorders. However, response to therapy varies and relapses are common, so an understanding of both inherited and acquired rituximab resistance is needed. In order to identify mechanisms...

詳細記述

書誌詳細

出版年:	PeerJ
主要な著者:	George W. Small, Howard L. McLeod, Kristy L. Richards
フォーマット:	論文
言語:	英語
出版事項:	PeerJ Inc. 2013-02-01
主題:	Rituximab Ofatumumab CD20 expression mRNA splice variants Complement-dependent cytotoxicity Drug resistance
オンライン･アクセス:	https://peerj.com/articles/31.pdf